European Hematology Association Congress (EHA)

The investigators concluded that the impact of autologous stem cell transplantation with ibrutinib cannot be determined vs ibrutinib alone.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

In BRUIN CLL-322, fixed-duration pirtobrutinib plus venetoclax/rituximab improved PFS vs venetoclax/rituximab in relapsed/refractory CLL.

Combining pirtobrutinib with venetoclax/rituximab yielded high MRD clearance among those with CLL/SLL in the phase 3 BRUIN CLL-322 trial.

In KOMET-007, ziftomenib plus 7+3 produced high responses and MRD-negativity rates in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.

The brentuximab vedotin-based regimen was consistently favored in sensitivity analyses regardless of covariate adjustment tested.

The use of CD20×CD3 bispecific antibodies correlated with lower hematologic toxicity, higher responses, and preserved CAR T fitness in LBCL groups.

MRD responses appeared to be more favorable with the use of blinatumomab among pediatric patients with high-risk B-cell acute lymphoblastic leukemia.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

In MonumenTAL-3, talquetamab plus daratumumab with or without pomalidomide significantly improved PFS vs DPd in relapsed/refractory myeloma.

Data from the MAXILUS study affirm the importance of early treatment initiation among those with lower-risk myelodysplastic syndrome.

High rates of MRD negativity were observed with a combination of carfilzomib, lenalidomide, daratumumab, and dexamethasone in the ASCENT trial.

There was no clear prognostic impact of age, comorbidities, complex living skills, or basic self-care tasks on PFS for diffuse large B-cell lymphoma.

A phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib showed composite complete remissions and MRD negativity in newly diagnosed IDH1-mutated AML.

The addition of epcoritamab to lenalidomide and rituximab showed improved efficacy and manageable safety in relapsed/refractory follicular lymphoma.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

Adverse drug reactions occurred in 1 patient treated with VT-EBV-N, although no grade 3 or higher events emerged.

“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, MBBS, PhD, MRCP, FRCPath.

Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.

The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the EHA 2025 Congress.